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1. Introduction 
 
This Statistical Analysis Plan (SAP) provides a detailed and comprehensive description of the main 
pre-planned analyses for the clinical trial "Improving the radical cure of P. vivax malaria (IMPROV): A 
multicentre randomised, placebo-controlled comparison of short and long course primaquine 
regimens”.  
The main purpose of the trial is to determine whether a 7-day primaquine regimen is safe and non 
inferior to the standard 14-day regimen (total dose of 7mg/kg in both arms) in preventing P. vivax 
relapse in G6PD normal patients. The study conduct is described in Protocol OXTREC 1014-13 and 
registered with ClinicalTrials.gov under NCT01814683. 
 
This document describes the statistical methods for the primary and secondary outcomes of the 
study as defined by the protocol as well as additional analyses of drug concentration data and a brief 
outline of further analyses in regards to parasite genetic studies, host genotyping, quantitative 
analysis of G6PD, evaluation of novel G6PD test and serology. The analysis plan for the economic 
component of the study will be presented separately. 
 
2. Study design and objectives 
2.1. Summary of trial design  
This is a randomized, double-blind, placebo-controlled, non-inferiority trial in G6PD normal patients 
with uncomplicated vivax malaria in the five participating study sites. Patients presenting to a 
participating treatment centre with uncomplicated vivax malaria and fulfilling the enrolment criteria 
will be randomly assigned to one of three treatment arms: 
 
- Intervention 1: Standard blood schizonticidal therapy plus 14 days of supervised primaquine 
(7mg/kg total dose) administered once per day (0.5 mg/kg). 
- Intervention 2: Standard blood schizonticidal therapy plus 7 days of supervised primaquine 
(7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo. 
- Control arm: Standard blood schizonticidal therapy plus 14 days placebo. 
 
Patients tested initially and found to be G6PD deficient will be excluded from the randomized study, 
but offered enrolment in a single arm non-randomised observational study to receive standard 
blood schizontocidal therapy plus primaquine 0.75 mg/kg/week for 8 weeks (total dose 6 mg/kg). 
 
All patients will receive standard medical care for the management of uncomplicated malaria, with 
blood schizontocidal treatment administered as either chloroquine (total dose 25 mg base/kg) or an 
artemisinin combination therapy such as a three-dose regimen of dihydroartemisinin-piperaquine, 
depending on local recommendations and known chloroquine efficacy. Recurrences of any species 
within 28 days will be considered treatment failures and treated with local second line alternatives 
(such as ACT or 7 days quinine) according to national guidelines. After 28 days, treatment failure is 
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less likely and so patients will be treated with the same treatment regimen as that allocated at 
enrolment. 
 
Primaquine/placebo will be administered with food (crackers or a biscuit), which has been shown to 
reduce gastrointestinal side effects. All doses of study drugs will be supervised. If participants cannot 
visit the study centre, or fail to attend during the 14 days of supervised therapy, team members will 
visit them in their homes or places of school or work to ensure complete dosing. Treatment efficacy 
and patient safety will be ensured by close monitoring over a 12 month follow up period following a 
schedule of visits and corresponding clinical and laboratory examinations. Individuals will be 
reviewed regularly and sampled for haemoglobin and blood film examination, the latter will be read 
immediately if the patient is symptomatic/febrile, or in a reference centre at a later date if the 
patient is well. Each symptomatic recurrence of P. vivax will be confirmed by microscopy and 
recorded. Intercurrent P. falciparum parasitaemia will be treated with the locally recommended ACT. 
2.2. Objectives 
Primary Objective 
 To determine whether a 7-day primaquine regimen is safe and non inferior to the standard 14-
day regimen (total dose of 7mg/kg in both arms) in preventing P. vivax relapse in G6PD normal 
patients. 
 
Secondary Objectives 
 To assess the absolute risks and benefits of radical treatment regimens in different endemic 
settings. 
 To provide data on the safety of a weekly dose of primaquine (0.75 mg base/kg) in patients with 
G6PD deficiency. 
 To identify the most cost-effective strategies for the management of P. vivax with respect to the 
use of G6PD tests, the dosing schedule and the epidemiological context (not covered in this SAP). 
 
2.3. Sample size 
The sample size calculation is based on an assumed incidence rate of 0.2 vivax infections per person-
year in both arms, a non-inferiority margin of 0.07 infections per person-year and a one-sided 
significance level of 2.5%. Based on these assumptions, a total sample size of 1200 evaluable 
patients, randomly allocated to receive a primaquine regimen (600 patients in each treatment arm), 
followed for one year will provide a power of 80% to show non-inferiority or, equivalently, that the 
two-sided 95% confidence interval for the difference in incidence rate of malaria between the two 
arms excludes an excess rate of 0.07 infections per person-year or more in favour of the 14 day 
regimen. A further 300 patients in the control arm will also be followed for one year. With 300 
patients in the control arm and 600 patients in each treatment arm (i.e. 75 controls and 150 patients 
in each treatment arm at each of the five study sites), the study has 95% power and 95% confidence 
to detect a difference (i.e. a superiority comparison of either regimen) at each of the study sites 
assuming an incidence rate of 0.2 infections per person-year in each of the treatment arms and 0.6 
infections per person-year in the control arm (ranging from 0.2 in the Indian subcontinent and 1.0 in 
Vietnam and Indonesia). The combined proportion of losses to follow-up and major protocol 
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violations is expected to be no more than 20%, so to account for this, a total of 1875 G6PD normal 
patients (750 per treatment arm; 375 in the control arm) will be randomized in this trial. In addition, 
up to 380 patients (approximately20% of the screened participants) with G6PD deficiency will be 
enrolled for the non-randomised observational study. 
3. Endpoints and Definitions 
3.1. Endpoints 
3.1.1. Efficacy Endpoints 
All efficacy endpoints refer to risk of recurrent parasitaemia which, unless otherwise specified, are 
based on microscopy  (table 1 provides an overview). 
3.1.1.1. Primary efficacy endpoints (Radical Cure) 
3.1.1.1.1. Incidence rate (per person year) of symptomatic recurrent P. vivax parasitaemia 
over 12 months of follow-up, for all individuals, controlling for site, comparing the 7 versus 14-
day primaquine treatment arms. 
3.1.1.2. Secondary efficacy endpoints (Radical Cure) 
3.1.1.2.1. Incidence rate (per person year) of symptomatic recurrent P. vivax parasitaemia 
over 12 months follow-up, for all individuals,  controlling for site, comparing the 7 and the 14-
day primaquine treatment arms with the control arm. 
3.1.1.2.2. The incidence rate (per person-year) of any recurrent (i.e. symptomatic and 
asymptomatic) P. vivax parasitaemia over 12 months of follow-up, for all individuals, 
controlling for site and comparing the 7 day with the 14- day primaquine regimen and the 
control arm with each primaquine regimen. 
3.1.1.2.3. The incidence risk (note, from hereafter in this document the incidence risk refers to 
the conditional probability of recurrence at time t, given the individual has not had a recurrence 
prior to this time, calculated using the Kaplan-Meier method) of symptomatic recurrence of P. 
vivax over 12 months of follow up, for all individuals, controlling for site, comparing the 7 day 
with the 14- day primaquine regimen and the control arm with each primaquine regimen. 
3.1.1.2.4. The incidence risk of any (symptomatic and asymptomatic) recurrence of P. vivax 
over 12 months of follow up, for all individuals, controlling for site comparing the 7 day with the 
14- day primaquine regimen and the control arm with each primaquine regimen. 
3.1.1.2.5. The incidence rate of any symptomatic parasitaemia (all species) over 12 months of 
follow-up, for all individuals, controlling for site, comparing the 7 day with the 14- day 
primaquine regimen and the control arm with each primaquine regimen. 
3.1.1.2.6. Incidence rate of any (symptomatic and asymptomatic) parasitaemia (all species) 
over 12 months of follow-up, for all individuals, controlling for site, comparing the 7 day with 
the 14- day primaquine regimen and the control arm with each primaquine regimen. 
3.1.1.2.7. The incidence risk of any symptomatic parasitaemia (all species) over 12 months of 
follow up, for all individuals, controlling for site, comparing the 7 day with the 14- day 
primaquine regimen and the control arm with each primaquine regimen. 
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3.1.1.2.8. The incidence risk of any (symptomatic and asymptomatic) parasitaemia (all 
species) over 12 months of follow up, for all individuals, controlling for site, comparing the 7 
day with the 14- day primaquine regimen and the control arm with each primaquine regimen. 
 
3.1.1.3. Secondary Efficacy endpoints (Schizontocidal Efficacy) 
All secondary efficacy endpoints refer to the treatment outcome following the first episode of P. 
vivax infection (enrolment episode) or the first symptomatic episode of P. falciparum. 
3.1.1.3.1. The incidence risk of P. vivax recurrence of the schizontocidal therapy at day 28 and 
42 in the control arm and in the intervention arms. 
3.1.1.3.2. PCR-adjusted incidence risk of P. vivax at day 28 and 42 in the control arms and in 
the intervention arms. 
3.1.1.3.3. Proportion of patients with P. vivax parasitaemia on days 1, 2 and 3 after 
schizontocidal treatment in the control arm. 
3.1.1.3.4. Proportion of patients with fever on days 1, 2 and 3 after schizontocidal treatment 
for P. vivax in the control arm. 
3.1.1.3.5.  Proportion of patients with P. falciparum parasitaemia on days 1, 2 and 3 after 
treatment of P. falciparum recurrent parasitaemia with ACT. 
 
 
 
Table 1: Primary and secondary efficacy endpoints (incidence risk and rate for radical cure and schizontocidal efficacy) 
 
Endpoint Number Risk/Rate Type of recurrence Duration of 
follow up, 
days 
Species of 
recurrence 
Comparison 
Primary 3.1.1.1.1 Rate Symptomatic 365 P. vivax 7 vs 14 
Secondary 3.1.1.2.1 Rate Symptomatic 365 P. vivax 7 vs control; 14 vs control 
Secondary 3.1.1.2.2 Rate Symptomatic & asymptomatic 365 P. vivax 7 vs 14; 7 vs control; 14 vs control 
Secondary 3.1.1.2.3 Risk Symptomatic 365 P. vivax 7 vs 14; 7 vs control; 14 vs control 
Secondary 3.1.1.2.4 Risk Symptomatic & asymptomatic 365 P. vivax 7 vs 14; 7 vs control; 14 vs control 
Secondary 3.1.1.2.5 Rate Symptomatic 365 All species 7 vs 14; 7 vs control; 14 vs control 
Secondary 3.1.1.2.6 Rate Symptomatic & asymptomatic 365 All species 7 vs 14; 7 vs control; 14 vs control 
Secondary 3.1.1.2.7 Risk Symptomatic 365 All Species 7 vs 14; 7 vs control; 14 vs control 
Secondary 3.1.1.2.8 Risk Symptomatic & asymptomatic 365 All Species 7 vs 14; 7 vs control; 14 vs control 
Secondary 3.1.1.3.1 Risk Symptomatic & asymptomatic 28/42 P. vivax 7 vs 14; 7 vs control; 14 vs control 
Secondary 3.1.1.3.2 Risk Symptomatic & asymptomatic, 
PCR adjusted 
28/42 P. vivax 7 vs 14; 7 vs control; 14 vs control 
 3.1.2. Safety Endpoints 
3.1.2.1. Risk of Haemolysis 
3.1.2.1.1. Incidence risk of severe anaemia (Hb<7g/dl) and/or the risk for blood transfusion 
within the 12 month follow up period. 
3.1.2.1.2. Incidence risk of an acute drop in Hb >5g/dl within 7 days of starting of primaquine 
treatment. 
3.1.2.1.3. Hb concentration  on day 3 and day 7. 
3.1.2.1.4. Hb nadir (defined as minimum Hb measurement during 28 days following 
treatment) and the median time at which it occurs.  
3.1.2.1.5. Area under the curve for day 0-28, 28-365 and 0-365, assuming the Hb value of day 
28 to be the normal value (see Figure 1 for example).  
Figure 1: Area under the curve 
 
 
3.1.2.2. Risk of adverse events 
3.1.2.2.1. Proportion of patients with vomiting within 1 hour of administration of a dose 
comparing the intervention arms and each intervention arm with the control arm. 
3.1.2.2.2. Proportion of patients with nausea, vomiting or abdominal pain comparing the 
intervention arms and each intervention arm with the control arm. 
3.1.2.2.3. The incidence risk of one or more adverse events and serious adverse events 
within 7, 14 and 42 days of the primary treatment comparing the intervention arms and each 
intervention arm with the control arm. 
3.1.2.2.4. The incidence rate of serious adverse event and serious adverse events over the 
study period comparing the intervention arms and each intervention arm with the control arm 
3.1.2.2.5. Proportion of patients completing a full course of all observed and blinded 
primaquine therapy comparing the intervention arms and each intervention arm with the control 
arm. 
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3.2. Definitions  
3.2.1. Symptomatic patients 
For the purpose of establishing the primary efficacy endpoints, “symptomatic patients” are defined 
as patients with P. vivax parasitaemia and either a documented fever (axillary temperature ≥37.5°C) 
or a history of fever within the preceding 48 hours. 
3.2.2. Study site 
A study site is defined as study location(s) under the responsibility of one local Principal investigator 
(PI) (e.g. one site could consist of two study hospitals in the same area under the responsibility of 
the same PI). 
3.3. Handling of missing data and adjudication of Endpoints 
3.3.1. Handling of missing data on drug course 
Patients can have an incomplete course of treatment or data on drug administration may be missing. 
No imputation of treatment course will be made for patients with missing data. Subgroup analyses 
will be performed for patients with full versus partial treatment courses (see section 4.9.3). 
3.3.2. Handling of missing data for Adverse Events 
For patients with missing data on adverse events the most conservative approach will be used: 
Deviation Action 
Start date of AE missing Assume during study drug intake 
End date of AE missing No imputation 
Date of start of study treatment 
administration missing 
All AEs after randomization considered to have happened 
during study drug intake 
Missing assessment of relationship to 
study treatment 
Assume event to be possibly related 
Missing severity assessment of AE Assume highest severity 
3.3.3. Adjudication of day 42-365 efficacy outcome assessment 
For missed visits during the 1 year follow up, the following rules will apply: 
Deviation Action 
More than 2 consecutive months without blood 
film examination  
-In the survival analysis lost to follow up (i.e. 
censored) on day of last visit before missing 
observation period. 
-In the incidence rate analysis using 
asymptomatic recurrences as the event, the 
period of missing observation will be deducted 
from the total period of observation. 
-In the incidence rate analysis using 
symptomatic recurrences as the event, the 
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period of missing observation will not be 
deducted from the total period of observation. 
3.3.4. Adjudication of day 28 and 42 efficacy outcome assessment 
The clinical definition of treatment failure enables determination of the efficacy endpoint for 
schizontocidal activity. However when the number of scheduled visits is incomplete the following 
rules will be applied1: 
3.3.5. Adjudication for endpoint on parasite prevalence on day 0-3 
For missed blood films (microscopy) the following rules will be applied1: 
Parasitaemia by microscopy Action 
Day 0 Day 1 Day 2 Day 3  
Yes Yes No Missing Assumed no parasitaemia on day 3  
Yes Yes Missing Yes Assumed parasitaemia on day 2  
Yes No Missing Missing Assumed no parasitaemia on day 2 and 3  
Yes Yes Missing No Will not contribute to proportion of patients with 
parasitaemia on day 2  
Yes No Missing No Assumed no parasitaemia on day 2  
Yes No Missing Yes Will not contribute to proportion of day 2 with 
parasitaemia  
Yes Yes Missing Missing Will not contribute to proportion of patients with 
parasitaemia on day 2 or 3  
3.3.6. Adjudication for endpoint on fever clearance on day 0-3 
For missed temperature records, the same rules as for missing blood slides will apply. 
3.3.7. Adjudication for haemoglobin outcome 
For missing haemoglobin measurements during follow up the following rules apply: 
Outcome assessment Deviation Action 
Incidence risk of severe 
anaemia within 12 months 
2 or more consecutive visits 
(only visits with scheduled Hb 
measurement) without Hb 
measurement  
lost to follow up on day of last 
visit before missing observation 
period 
                                                             
1 WWARN. Clinical Module, Data Management and Statistical Analyses Plan. 2013; Available from: 
http://www.wwarn.org/sites/default/files/ClinicalDMSAP.pdf 
Outcome 
assessment 
Deviation Action 
Day 28 and 42 More than 18 days without blood smear 
results  
Lost to follow up on the day 
of last observation 
Day 28 No blood smear results between  day 25 and  
day 31 
Lost to follow up on day of 
last visit before day 25 
Day 42 No blood smear results between  day 39 and 
day 45 
Lost to follow up on day of 
last visit before day 39 
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Incidence risk of Hb drop within 
7 days after PQ treatment 
Missing Hb measurement on 
day 3  
 
Missing Hb measurement on 
day 7, but present on day 3 
Censored on day 0 
  
 
Censored on day 3  
Hb level on day 3  Missing Hb measurement on 
day 3  
Exclude from analysis 
Hb level on day 7 Missing Hb measurement on 
day 7 
Exclude from analysis 
Hb nadir (during 28 days FU) 2 or more consecutive 
scheduled visits within 28 days  
without Hb measurement 
Excluded from analysis 
 
 
Area under the curve 
 
One scheduled visit without Hb 
measurement 
 Interpolate Hb from the two 
neighbouring values 
More than one missing 
scheduled visit without Hb 
measurement 
Exclude from analysis 
 
3.4. Analyses Populations 
3.4.1. Efficacy population 
For the efficacy analysis, both an intention-to-treat (ITT) and a per-protocol (PP) approach will be 
adopted. The ITT analysis will be the primary approach for comparison of the different drug 
treatments.  
3.4.1.1. Intention to Treat 
To provide a pragmatic comparison of the different drug treatments, the principle of intention-to-
treat, will be the main strategy of analysis adopted for the primary and secondary endpoints. These 
analyses will be conducted on all patients assigned to the treatment groups as randomized, 
regardless of the study treatment received.  
3.4.1.2. Per Protocol 
An analysis based on a "per protocol" approach will be conducted. The following will lead to 
exclusion in the per protocol analyses: 
 Ineligibility (either arising during the study or retrospectively having been overlooked at 
screening) 
 Significant protocol deviation e.g. given wrong total dose of primaquine/placebo 
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3.4.2. Safety population 
For the analysis of safety outcomes, all patients who received any study drug are included in the 
safety analysis in the treatment group they actually received.  This means also patients having 
vomited the first dose and having had their treatment discontinued will be included in this analysis.  
3.4.3. Pharmacokinetic population 
For the analyses of drug concentrations all patients who had at least one blood sample taken and 
measured will be included in the analysis, even if the measure was below the limit of quantification. 
4. Analyses 
4.1. General analyses strategy 
The primary analysis will use the combined data from all sites and countries together, with 
adjustment for site effects. In addition, treatment effects will be estimated within each site, but 
formal assessment of non-inferiority will not be performed for each site, since the study is not 
powered for this comparison. 
4.2. Pooling across sites 
As this is a randomized trial, with a common protocol and data collection and review tools across all 
sites, this pooled approach is expected to be valid. However, evidence for heterogeneity will be 
visually assessed and tested before deciding whether pooling of data across sites is justified. 
4.3. Assessment of heterogeneity 
There is an expected degree of heterogeneity of exposure in different endemic settings, which might 
lead to heterogeneity between study sites (as defined in section 3.2.2) regarding the treatment 
effect. Heterogeneity between study sites will be assessed visually using Forrest plots of the site 
specific differences in incidence rates of vivax recurrence. I-squared values (percentage of total 
variation across studies due to heterogeneity) will also be calculated to assess statistically the degree 
of heterogeneity.  
If substantial levels of heterogeneity are detected, site specific analyses will be performed only. If no 
substantial levels of heterogeneity are detected, then pooled analyses will be performed. 
4.4. Demographic and baseline characteristics 
Details of all patients screened, those who meet the study inclusion criteria, those who are eligible 
and randomized, those who are eligible but not randomized, those who withdraw from the study 
after randomization and those who are lost to follow-up will be summarized in a CONSORT flow 
diagram.  
The number of patients discontinuing from the study will be tabulated by reason for study 
discontinuation. The number (%) of patients attending scheduled follow-up visits by study day (days 
1 to 28 and 42, monthly visits until 1 year) will be reported. 
The baseline value is defined as the last available value before randomization. 
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4.4.1. Demographic characteristics 
• Gender: male / female 
• Median Age (years), 25th-75th percentiles, and range  
• Age in classes: 12 months up to 5 years, 5 years up to 15 years, ≥15 years 
 Median Weight (kg), 25th-75th percentiles, and range  
• Weight in classes: <9kg / 9-<18 kg/ 18 - <36 kg / ≥ 36 kg 
 
4.4.2. Disease characteristics at baseline 
Specific disease history will include the parasite and gametocytes densities (/µL) at day 0, as well as 
axillary temperature (°C) (quantitative and if <37.5°C), Median Pulse rate (beats/min), 25th-75th 
percentiles, and range and signs and symptoms (weakness, headache, anorexia, nausea, vomiting, 
pain, diarrhoea, convulsion, dehydration, icterus, sweat, chills, skin disorders) at day 0. 
4.4.3. Prior or concomitant medications 
All medications taken within 28 days before randomization and until the end of the study will be 
reported in the case report form pages. 
All medications will be coded using the World Health Organization-Drug Dictionary (WHO-DD) or 
equivalent dictionaries. 
 Prior medications are those the patient used prior (28 days before) to first study drug intake. 
Prior medications can be discontinued before first administration or can be ongoing during 
treatment phase.  
 Concomitant medications are those used during the treatment with the study drug and 
during the first phase of follow up until day 42. Concomitant medications can be ongoing 
prior medication and/or continue into post treatment medication. 
 Post treatment medications are those the patient took in the period from day 43 until the 
end of the study. 
 
4.5. Efficacy analyses 
Effective treatment with schizontocidal and hypnozontocial activity is referred to as radical cure. The 
efficacy is confounded by exposure to reinfection.  The primary analysis will focus on the overall 
efficacy of radical cure (see 4.5.1). The secondary analyses will investigate the subcomponents of 
schizontocidal efficacy (see 4.5.2). 
4.5.1. P. vivax radical cure 
In the course of the follow up patients will only be tested for malaria if they have concomitant fever 
or a history of fever. If the blood film is positive for any blood stage Plasmodium, schizontocidal 
treatment will be initiated. If P. vivax is detected ≥28 days after initial enrolment, the patient will 
also receive primaquine treatment in the same regimen the patient was allocated to at enrolment. 
There will be a maximum of four repeated P. vivax episodes treated with the originally assigned 
primaquine regimen (three in the case of Vietnam). Patients with their fifth or subsequent episode 
will be treated with open primaquine at a dose of 0.5mg/kg x 14 days and will be censored 
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thereafter from the primary outcome, but remain in the study for further follow up and 
documentation of secondary outcomes. 
4.5.1.1. Incidence rates 
The overall primary endpoint for radical cure will be the incidence rate of recurrent episodes of 
symptomatic P. vivax parasitaemia (alone or mixed species infections). Incidence rates will be 
calculated by dividing the number of symptomatic P. vivax episodes by the number of person-years 
of observation (PYO) in the study population. The start date for PYO will be the day of enrolment 
into the study and the stop date the last visit performed (either completed study at 1 year or any last 
visit before lost to follow up and/or censoring). The period between start and stop dates for each 
patient will be calculated in days and divided by 365 to determine PYO, which will then be totalled 
for all participants. 
For the primary endpoint comparison the absolute difference in the incidence rates between the 
treatment arms will be presented. Comparison between secondary incidence rate endpoints will be 
based on the relative difference and will therefore be presented as Incidence Rate Ratio (IRR) 
derived from a negative binomial regression model. 
The effect of post-treatment prophylaxis on the time of observation will be assessed as follows in 
three sensitivity analyses: 
 (i) Patients receiving antimalarial treatment during follow up will be assumed to have a 
period of 28 days of post- treatment prophylaxis in the case where they received 
chloroquine (CQ) or Dihydroartemisinin-piperaquine (DHA-PIP) and 14 days in the case 
where they received artemether-lumefantrine (AL).  This period will thus be subtracted 
from their total period of follow up. In case patients receiving rescue treatment with 
quinine a total of 14 days will be subtracted. 
 (ii) Patients receiving antimalarial treatment during follow up will be assumed to have a 
period of 14 days of post-treatment prophylaxis independent of the treatment received. 
This period will thus be subtracted from their total period of follow up. 
 (iii) Patients receiving antimalarial treatment during follow up will be assumed to have no 
period of post-treatment prophylaxis and no time period will therefore be subtracted from 
their total period of follow up. 
All routine slides including those from asymptomatic individuals will be read at a later date. A 
secondary measure of hypnozontocidal activity will therefore be the total number of blood film 
examinations documenting parasitaemia 14 days or more after antimalarial treatment. This 
secondary incidence rate of symptomatic and asymptomatic parasitaemia will be presented.  
 
All sites except one will provide the same treatment as originally randomized for up to 4 repeated 
episodes of P. vivax during follow up. The site in Vietnam will only provide the same treatment until 
the 3rd episode and thereafter treat patients with open primaquine for the subsequent episodes. 
For the overall incidence analyses two sensitivity analyses will therefore be performed: 
i) Overall, excluding the data from Vietnam 
ii) Overall, including the data from Vietnam but censoring all patients at the time point of the 
third episode in the other countries. 
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4.5.1.2. Incidence risk 
The incidence risk (95% CI) of parasite recurrence within 12 months follow-up will be calculated 
using the Kaplan-Meier (KM) method for each trial arm  as well as a comparison of the relative 
hazards between trial arms (Hazard Ratio (95% CI)) estimated from a Cox regression analysis for the 
time to the first recurrent episode with stratification for study site. Patients who are categorized as 
lost to follow up (as defined in section 3.3.3) will be censored at the day of the last visit. 
Separate analyses will be performed for the incidence risk of any symptomatic P. vivax parasitaemia, 
for symptomatic and asymptomatic episodes of P. vivax and for any Plasmodium parasitaemia. 
4.5.2. P. vivax schizontocidal efficacy 
Schizontocidal antimalarial efficacy will be documented at day 28 and day 42. Although the primary 
episode at enrolment to the study will be P. vivax, subsequent episodes will also include non P. vivax 
species. Schizontocidal efficacy for P. vivax will be estimated only for the enrolment episode.  
Detection of non-vivax parasitaemia before day 28 or 42 of follow up will result in antimalarial 
treatment, and thus censoring of the patient for the schizontocidal efficacy analyses (secondary 
endpoint). In the case of parasitaemia without P. vivax (i.e. P. falciparum or P. malariae) the 
individual will be considered as censored on the first day of parasitaemia. If P. vivax is observed 
either alone or mixed with other species then the individual will be considered as a treatment 
failure. Patients who are categorized as lost to follow up (as defined in section 3.3.4 and 3.3.3) will 
be censored at the day of the last visit. 
The incidence risk of recurrent parasitaemia will be calculated as described in section 4.5.1.2 at day 
28 and 42 instead of 12 months. 
Additional measures for schizontocidal efficacy are parasite clearance time (PCT) and fever clearance 
time (FCT), which are not confounded by potential relapses2. Delayed clearance has been found to 
be a predictor for recurrence by day 28 and 42. Parasite prevalence on days 1, 2 and 3 will therefore 
be presented. 
4.5.3. P. falciparum schizontocidal efficacy 
Schizontocidal efficacy estimates for P. falciparum will only be estimated for the first symptomatic P. 
falciparum episode after enrolment. 
Detection of non-falciparum parasitaemia before day 28 or 42 of follow up will result in antimalarial 
treatment, and thus censoring of the patient for the schizontocidal efficacy analyses (secondary 
endpoint). In the case of parasitaemia without P. falciparum (i.e. P. vivax or P. malariae) the 
individual will be considered as censored on the first day of parasitaemia. 
4.6. Primary efficacy analyses (Radical Cure) 
4.6.1. Incidence rate of symptomatic P. vivax parasitaemia over 12 months 
The primary analysis for the incidence rate of symptomatic P. vivax parasitaemia over 12 months 
will be calculated as described in section 4.5.1.1.  The 7-day treatment will be considered non-
inferior to the 14-day treatment if the upper limit of the two-sided 95% confidence interval is lower 
                                                             
2 Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Price R et 
al. Lancet Infect Dis. 2014 Oct;14(10):982-91.  
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than 0.07 P. vivax infections per person-year. The analyses will be performed in the ITT and the PP 
population (see 3.4.1) and as follows: 
 for all sites combined, controlling for site  
o excluding Vietnam 
o including the data from Vietnam, but censoring all patients at the time point of the 
third episode in the other countries 
 
4.7. Secondary efficacy analyses (Radical Cure) 
4.7.1. Incidence rate of symptomatic P. vivax parasitaemia over 12 months 
The analysis for the incidence rate of symptomatic P. vivax parasitaemia over 12 months will be 
calculated as described in section 4.5.1.1. The following comparisons will be performed: 
 7 day regimen versus control 
 14 day regimen versus control 
The analyses will be performed in the ITT and the PP population (see 3.4.1) and as follows: 
 for all sites combined, controlling for site 
o excluding Vietnam 
o including the data from Vietnam, but censoring all patients at the time point of the 
third episode in the other countries 
 
4.7.2. Incidence rate of any P. vivax parasitaemia over 12 months  
The analysis for the incidence rate of symptomatic & asymptomatic P. vivax parasitaemia over 12 
months will be calculated as described in section 4.5.1.1. The following comparisons will be 
performed: 
 7 days versus 14 day regimen. 
 7 day regimen versus control 
 14 day regimen versus control 
The analyses will be performed in the ITT and the PP population (see 3.4.1) and as follows: 
 for all sites combined, controlling for site 
o excluding Vietnam 
o including the data from Vietnam, but censoring all patients at the time point of the 
third episode in the other countries 
4.7.3. Incidence risk of symptomatic recurrence of P. vivax over 12 months  
This analysis will be performed as described in section 4.5.1.2. The first recurrent symptomatic 
episode of P. vivax will be treated as failure endpoint. Patients presenting with symptomatic 
parasitaemia other than P. vivax will be censored at the day or occurrence. Patients with 
asymptomatic parasitaemia will be censored at the time of occurrence. 
Comparisons will be made between the three regimens. The analyses will be performed in the ITT 
and the PP population (see 3.4.1) for all sites combined, controlling for site. 
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4.7.4. Incidence risk of any recurrence of P. vivax over 12 months 
This analysis will be performed as described in section 4.5.1.2. The first recurrent symptomatic or 
asymptomatic episode of P. vivax will be treated as failure endpoint. Patients presenting with 
parasitaemia (symptomatic & asymptomatic) other than P. vivax will be censored at the day or 
occurrence.  
Comparisons will be made between the three regimens. The analyses will be performed in the ITT 
and the PP population (see 3.4.1) for all sites combined controlling for site. 
4.7.5. Incidence rate of any symptomatic parasitaemia over 12 months 
The analysis for the incidence rate of any symptomatic parasitaemia (P. vivax & any other 
Plasmodia) over 12 months will be calculated as described in section 4.5.1.1. The following 
comparisons will be performed: 
 7 day regimen versus control 
 14 day regimen versus control 
The analyses will be performed in the ITT and the PP population (see 3.4.1) and as follows: 
 for all sites combined, controlling for site  
o excluding Vietnam 
o including the data from Vietnam, but censoring all patients at the time point of the 
third episode in the other countries 
4.7.6. Incidence rate of any parasitaemia over 12 months 
The analysis for the incidence rate of any symptomatic parasitaemia (P. vivax & any other Plasmodia) 
over 12 months will be calculated as described in section 4.5.1.1. The following comparisons will be 
performed: 
 7 day regimen versus control 
 14 day regimen versus control 
The analyses will be performed in the ITT and the PP population (see 3.4.1) and as follows: 
 for all sites combined, controlling for site  
o excluding Vietnam 
o including the data from Vietnam, but censoring all patients at the time point of the 
third episode in the other countries 
4.7.7. Incidence risk of any symptomatic parasitaemia over 12 months 
This analysis will be performed as described in section 4.5.1.2. The first recurrent symptomatic 
episode of any parasitaemia will be treated as failure endpoint. Patients presenting with any 
asymptomatic parasitaemia will be censored at the day or occurrence.  
Comparisons will be made between the three regimens. The analyses will be performed in the ITT 
and the PP population (see 3.4.1) for all sites combined, controlling for site. 
4.7.8. Incidence risk of any parasitaemia over 12 months 
This analysis will be performed as described in section 4.5.1.2. The first recurrent symptomatic or 
asymptomatic episode of any parasitaemia will be treated as failure endpoint. No parasitaemia will 
lead to censoring. 
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Comparisons will be made between the three regimens. The analyses will be performed in the ITT 
and the PP population (see 3.4.1) for all sites combined, controlling for site. 
4.8. Secondary efficacy analyses (Schizontocidal Efficacy) 
4.8.1. Schizontocidal efficacy of chloroquine and chloroquine plus primaquine at day 28 
and 42  
The incidence risk is the time to the first event (recurrence of P. vivax) and will be assessed using 
survival analyses (Kaplan Meier). Therapeutic efficacy of the schizontocidal treatment in the control 
arm will be assessed at day 28 and 42. Patients presenting with parasitaemia other than P. vivax will 
be censored at the day or occurrence. The analyses will be performed for all sites combined, 
controlling for site (see also section 4.5.2). The incidence risk of P. vivax recurrence will be compared 
between the control arm (chloroquine alone) and each intervention arms. 
4.8.2. PCR-adjusted incidence risk of P. vivax at day 28 and 42 
The incidence risk of recurrent P. vivax over 28 and 42 days will be assessed by survival analysis 
(Kaplan Meier method) (see also 4.5.1.2), but parasites with different genotypes will be censored 
from the analysis. If in all of the markers used at least one allele is matching in the enrolment sample 
and in the sample taken at the day of recurrence, the recurrence will be considered the same 
infection. Otherwise, it will be considered a different infection. In the event that molecular data is 
missing from the day of recurrence, the patient will be censored at this day without a recorded 
endpoint outcome (i.e., that patient will not contribute any influence on the risk estimate). 
Comparison will be made between the different treatment arms. The analyses will be performed for 
all sites combined, controlling for site. 
4.8.3. Proportion of patients with P. vivax parasitaemia on day 1, 2 and 3 after 
schizontocidal treatment in the control arm 
Parasite clearance will be presented using the proportions of patients who remain parasitaemic on 
each day (days 1 to 3).  
4.8.4. Proportion of patients with fever on day 1, 2 and 3 after schizontocidal treatment 
for P. vivax in the control arm 
Fever clearance time will be presented as the proportion of patients who were febrile or had a 
history of fever on day 0 and who became febrile (<37.5°C) day 1, 2 and 3 with no subsequent 
measured fever or history of fever on subsequent daily within the next 48 hours.  
4.8.5. Proportion of patients with P. falciparum parasitaemia on day 1, 2 and 3 after 
treatment with ACT during follow up 
In the course of the follow up patients will present with P. falciparum infections. Those patients are 
treated and followed until parasite clearance. Parasite clearance of P. falciparum cases occurring 
during the follow up will be presented using the proportions of patients who remain parasitaemic on 
each day (days 1 to 3). Only the first episode of P. falciparum during follow up will be used for this 
analysis. 
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4.8.6. Proportion of patients with fever on day 1, 2 and 3 after schizontocidal treatment 
for P .falciparum during follow up 
As described in section 4.8.5 patients will present with P. falciparum infections. Fever clearance of P. 
falciparum cases occurring during the follow up will be calculated as described in section 4.8.4. Only 
the first episode of P. falciparum during follow up will be used for this analysis. 
 
4.9. Additional analyses: 
4.9.1. Incidence risk of P. falciparum after P. vivax infection 
This analysis will look into the time to the first recurrence of P. falciparum after the initial P. vivax 
infection and will be assessed using survival analyses (Kaplan Meier method). Patients enrolled with 
P. vivax will be included in the analyses. Patients presenting with P. falciparum parasitaemia after 
the initial P. vivax infection are defined as failures. Patients presenting with a recurrent pure P. vivax 
infection or any other parasitaemia other than P. falciparum will be censored at the time of 
occurrence. The analyses will be performed for all sites combined, controlling for site. Comparisons 
will be made between the control arm and the 7 day regimen as well as between the control arm 
and the 14 day regimen (see also section 4.5.2). 
4.9.2. Incidence risk of P. vivax after first P. falciparum infection 
This analysis will look into the time to a recurrence of P. vivax after the first P. falciparum infection 
and will be assessed using survival analyses (Kaplan Meier method). Patients with P. falciparum 
infection during follow up will be included in the analyses, starting their exposure time from the time 
the first P. falciparum infection occurred. Patients presenting with P. vivax parasitaemia thereafter 
are considered failures for the purpose of this analysis. Patients presenting with a recurrent P. 
falciparum infection or any other parasitaemia other than P. vivax will be censored at the time of 
occurrence. The analyses will be performed for all sites combined, controlling for site. Comparisons 
will be made between the control arm and the 7 day regimen as well as between the control arm 
and the 14 day regimen (see also section 4.5.2). 
4.9.3. The distribution of P. vivax recurrences in the control arm 
The analysis for the incidence rate of symptomatic P. vivax recurrence over 12 months in the control 
arm will be calculated as described in section 4.5.1.1 and compared between sites and regions. 
4.9.4. Subgroup analyses 
A priori subgroup analyses will be performed for the incidence rate and risk of symptomatic P. vivax 
parasitaemia over 12 months (see section 4.6.1, 4.7.1, 4.7.3 ) in the following subgroups:  
 By age group: to assess the treatment efficacy and risk of recurrence by age. 
• By site and region: to compare the protective efficacy of primaquine in areas with different 
vivax relapse periodicity  
• Patients with full versus partial treatment courses: to assess the impact of the duration of 
treatment and total amount of primaquine received. 
• By schizontocidal drug: to assess whether efficacy varies with schizontocidal partner drug. 
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4.10. Safety analyses 
The primary safety concerns regarding primaquine use pertain to the risk of haemolysis and 
gastroenterological adverse events.  All safety analyses will be assessed in patients whose treatment 
remains blind; once treatment is un-blinded (i.e. in the case of five or more episodes of P. vivax 
malaria) then these patients will be censored from further safety analyses. 
4.10.1. Risk of Haemolysis 
4.10.1.1. Incidence risk of severe anaemia or transfusion 
Safety of primaquine treatment in the 7 day and the 14 day regimen will be compared by calculating 
the incidence risk of severe anaemia (Hb<7g/dl) and/or blood transfusion within the 12 month 
follow up. Incidence risk will be calculated as described in section 4.5.1.2. using the Kaplan-Meier 
method. Patients who develop severe anaemia will be considered failures. Patients lost to follow up 
or with missing measurements will be censored at the time of the last visit (see 3.3.7). Comparisons 
will be performed between the 7 day and 14 day regimen and the G6PDd and the control arm by 
comparing the relative hazards (Hazard Ratio (95% CI)) estimated from a Cox regression analysis with 
stratification for study site. 
4.10.1.2. Incidence risk of drop in Hb >5g/dl 
Safety of primaquine treatment will be compared by calculating the incidence risk of an acute fall in 
Hb >5g/dl within 7 days of starting of primaquine/placebo treatment. Incidence risk will be 
calculated as described in section 4.5.1.2 using the Kaplan-Meier method. Patients with an acute 
drop of Hb >5g/dl will be considered as failures. Patients lost to follow up or with missing 
measurements will be censored at the time of the last visit (see 3.3.7). Comparisons will be 
performed between the 7 day and 14 day regimen and the G6PDd and the control arm. 
4.10.1.3. Hb level day 3 and day 7 
For changes in Hb concentration between baseline and day 3 or day 7, linear mixed-effects 
modelling will be performed with an interaction term between treatment group and time to assess if 
changes in Hb vary between the intervention arms and the intervention and control arms, with 
random effects for the intercept and slope. Comparisons will be made between the intervention 
arms, the intervention arms and the control group and between the G6PDd arm and the control 
group. 
4.10.1.4. Hb nadir after treatment and the median time at which it occurs 
The Hb nadir will be defined as the minimum Hb measurement during 28 days follow up after 
initiation of treatment. Estimated mean Hb concentrations will be compared between the 
intervention arms and also between each intervention arm and the control group using multivariable 
linear regression with adjustment for site. The median time from enrolment until the nadir is 
reached will be calculated for the different treatment groups and compared using multivariable 
linear regression with adjustment for site. 
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4.10.1.5. Area under the curve 
The area under the curve will be calculated assuming that a patient’s normal Hb is reflected by their 
Hb on day 283. Initial exploration will define whether day 28 or an alternative day is the most 
appropriate measure. The area under the curve will be presented for the following periods: day 0-
28, day 28-365 and day 0- day 365. The estimated mean area under the curve will be compared 
between the intervention arms and also between each intervention arm and the control group using 
multivariable linear regression with adjustment for site. 
 
4.10.2. Risk of Adverse Events 
4.10.2.1. Risk of acute vomiting 
Proportion of patients with vomiting within 1 hour of administration of a dose will be calculated for 
each arm. The absolute difference between the intervention arms and between each intervention 
arm and the controls will be presented. 
4.10.2.2. Risk of gastroenterological events 
Proportion of patients with nausea, vomiting, abdominal pain or vomiting will be calculated for each 
arm. Proportions for each symptom will be calculated separately. The absolute difference between 
the intervention arms and between each intervention arm and the controls will be presented. 
4.10.2.3. Overall risk of Adverse Events (AE) and Serious Adverse Events (SAE) 
The proportion of patients with one or more adverse events and serious adverse events within 7, 14 
and 42 days of their primary treatment will be presented. Events will be divided into related and 
unrelated events in regards to the treatment. The absolute difference between treatment groups in 
the proportion of patients (two-sided 95% CI) with AEs and SAEs will be calculated for those time 
points. 
4.10.2.4. Adherence 
The proportion of patients completing a full course of observed primaquine therapy will be 
calculated for each arm. The absolute difference between the intervention arms and between each 
intervention arm and the controls will be presented. 
 
4.11. Pharmacokinetic analyses 
4.11.1. Chloroquine  
The schizontocidal efficacy of chloroquine depends on adequate absorption of drug. For long half-life 
drugs the day 7 concentrations are a good predictor of the drug exposure (i.e. area under the drug 
concentration versus time profile). 
Mean drug concentration of CQ will be assessed at day 7 as a measure of drug exposure. For 
patients that fail (defined as a recurrence of P. vivax) during the follow up the mean (95%CI) drug 
levels at day 7 and the day of recurrence will be presented and mean day 7 measurements 
                                                             
3 Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Price R et al. 
Am J Trop Med Hyg. 1999 Apr;60(4):547-55. Review. 
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compared using the two-sample t test. The proportion of patients with recurrences that present 
with any CQ concentrations and those without CQ in their peripheral blood will be tabulated. 
Further the proportion of patients with levels ≥100ug/ml and the proportion of patients <100ug/ml 
will be presented. Patients with adequate drug levels at the day of recurrence are indicative to carry 
CQ resistant parasites. 
4.11.2. Primaquine 
Primaquine has a short half-life, whereas its metabolite Carboxy-Primaquine stays longer in the 
peripheral blood stream. Samples will be taken on day 7 and 13/14. The analyses will aim to 
establish the normal concentration of Carboxy-Primaquine after 7 and 14 days of supervised 
primaquine treatment in the two intervention arms and the control arm (e.g. present a standard 
curve of Carboxy-Primaquine over 14 days supervised treatment). 
In addition we will perform multivariable logistic regression to understand the relationship between 
drug concentration at day 7 and 14 and the binary outcome at 12 months, radical cure (yes versus 
no) with adjustment for site. 
 
